Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993731 · ClinicalTrials.gov registry record · Phase 3
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,134
- Enrollment target
NCT02993731: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT02993731 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 1,134 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993731, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,134 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Primary Outcome
To assess the effect of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine on the Overall Survival of patients with metastatic pancreatic ductal adenocarcinoma.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Napabucasin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,134 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-03 |
| Phase | Phase 3 |
What the finished NCT02993731 record still lists
NCT02993731 is an interventional study that assigns participants to a tested intervention. Its 1,134 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02993731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02993731 about?
NCT02993731 is a clinical study titled "A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma". This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
What is the current status of trial NCT02993731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,134 participants. The study started on 2016-12. Estimated completion is 2020-03.
What interventions are being tested in trial NCT02993731?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Napabucasin (DRUG).
Who is sponsoring clinical trial NCT02993731?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02993731's enrollment target sits among peer trials
1,134 244th of 2000 higher than 1,757 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia